Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit
May 18 2023 - 10:00AM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced the first
commercial shipment of its BioXp® NGS Library Prep kit for Plasmid
Sequencing. This NGS Library Prep kit enables on-demand and
automated library preparation of plasmid DNA for use in
next-generation sequencing applications.
Leveraging this new automation capability of the BioXp® platform
is expected to enable researchers in high-throughput discovery
workflows to reduce hands-on time, cost, and steps of NGS Library
Preparation, both accelerating their time to answer and reducing
barriers to access to Next-Generation Sequencing.
“This kit represents a major milestone in the evolution of the
BioXp® System as it now provides customers with a complete solution
in many synthetic biology and genomics workflows. Throughout 2023
we plan to continue to expand capabilities for NGS Library
Preparation as well as for DNA and mRNA synthesis beginning from
the customer’s sequence, linear DNA, or plasmid DNA. We believe
that this transformation of the BioXp platform to an automated
molecular biology workstation, will empower researchers with an
integrated workflow solution to streamline synthetic biology and
multiomic applications throughout discovery. Thus, creating
efficiencies in and accelerating their overall discovery process,”
said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.
“In our work manufacturing plasmid DNA for vaccine, gene
therapy, or other R&D applications, it is critical to confirm
the quality of our end product through DNA sequencing, but the
commonly employed sample preparation methods are time consuming and
labor intensive. We are pleased to be an Early Access partner with
Telesis Bio as we believe their vision for the BioXp platform can
help further accelerate and streamline our workflow,” said Santhosh
Kallivalappil, Co-founder & Executive Director R&D of Novel
Biotechnologies Inc.
For more information on BioXp® NGS Library Prep Kits
please visit: telesisbio.com/products/bioxp-kits/ngs/
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® systems consolidate, automate,
and optimize the entire synthesis, cloning and amplification
workflow. As a result, they deliver virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
About Novel Biotechnology Inc.
Novel Biotechnology Inc. is on a mission to develop disruptive
platforms that address unmet needs in the life sciences and
pharmaceutical domains. Their focus is on developing new solutions
for manufacturing plasmid DNA, a critical starting material for
gene therapy, cell engineering, mRNA therapy and vaccine
applications. They are developing a platform that is safe,
scalable, adaptable to different plasmid backbones and payloads,
has improved product quality, and is many times more productive
than existing systems. Through their services business, they are
currently offering plasmid DNA manufacturing services to a growing
base of customers.
Forward-Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements and guidance regarding Telesis Bio’s future
financial performance as well as statements regarding the future
release and success of new and existing products and services. Such
statements are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond our control, include risks described in the section entitled
Risk Factors and elsewhere in our Quarterly Report on Form
10-Q, which was filed with the Securities and Exchange Commission
on May 12, 2023. These forward-looking statements speak only as of
the date hereof and should not be unduly relied upon. Telesis Bio
disclaims any obligation to update these forward-looking
statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024